Abstracts tagged "Cardiovascular disease"

Abstract Number: 293 • 2015 ACR/ARHP Annual Meeting
Measurement of Advanced Glycation Endproducts in the Skin of Patients with Idiopathic Inflammatory Myopathies
Simone Barsotti¹, Chiara Saponaro², Rosaria Talarico³, Alessandra Tripoli⁴, Claudia Ferrari⁵, Elisabetta Bianchini⁶, Nicole Di Lascio⁶, Melania Gaggini², Amalia Gastaldelli², Marta Mosca⁷, Maria Aurora Morales⁶ and Rossella Neri⁵, ¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²National Research Council, Institute of Clinical Physiology, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵Internal Medicine, University of Pisa, Pisa, Italy, ⁶Institute of Clinical Physiology, CNR, Pisa, Italy, ⁷University of Pisa, Pisa, Italy
Background/Purpose: Many data suggest that advanced glycation endproducts (AGEs) play an important role the development of atherosclerosis and cardiovascular (CV) disease. AGEs are produced and…
Abstract Number: 1505 • 2015 ACR/ARHP Annual Meeting
Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression over 24 Weeks
Tatiana Nevskaya¹, Janet E. Pope², Lillian Barra³ and Grace Parraga⁴, ¹Medicine, Division of Rheumatology, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁴University of Western Ontario, Robarts Research Institute, London, ON, Canada
Background/Purpose: This study evaluated the prevalence and progression of subclinical carotid artery atherosclerosis in active rheumatoid arthritis (RA). Methods: Carotid arteries of RA patients were scanned…
Abstract Number: 1568 • 2015 ACR/ARHP Annual Meeting
Cardiac Morphology and Function in Patients with Acute Coronary Syndrome Complicated with Rheumatoid Arthritis
Li-Li Pan¹ and Tian Wang², ¹Rheumatology and Immunology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China, ²1. Department of Rheumatology and Immunology,, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China
Background/Purpose: Cardiovascular diseases are important contributors to the excess of overall morbidity and mortality in patients with rheumatoid arthritis (RA). The aim of this study…
Abstract Number: 2126 • 2015 ACR/ARHP Annual Meeting
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
George D. Kitas¹, Peter Nightingale², Jane Armitage³, Naveed Sattar⁴, Jill Belch⁵, Deborah P.M. Symmons⁶ and TRACE RA Consortium, ¹Dudley Group NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Clinical Trial Service Unit and Epidemiology Unit, University of Oxford, Oxford, United Kingdom, ⁴University of Glasgow, BHF Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, ⁵Division of Cardiovascular and Diabetes Medicine, University of Dundee, Dundee, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) compared to the general population, both due to classical and novel…
Abstract Number: 3064 • 2015 ACR/ARHP Annual Meeting
Cardiac Manifestation of Takayasu Arteritis
Jin Wan, rheumatology and immunology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China
Background/Purpose: To explore cardiac manifestation of Takayasu arteritis and independent risk factor. Methods: We retrospectively analyzed manifestations and helpful tests in 55 TA patients. …
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting
EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…
Abstract Number: 1574 • 2015 ACR/ARHP Annual Meeting
Associations of Serum Anti-Malondialdehyde-Acetaldehyde (MAA) Antibodies with Cardiovascular and Respiratory Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell Klassen⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Daniel Anderson⁷, Harlan Sayles⁷, Kaleb Michaud⁸, Liron Caplan⁹, Lisa A. Davis⁹, Grant W. Cannon¹⁰, Brian Sauer¹¹, E. Blair Solow¹², Andreas Reimold¹³, Gail S. Kerr¹⁴, Pascale Schwab¹⁵, Joshua F. Baker¹⁶ and Ted R. Mikuls¹⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Research Services 151, Omaha VA Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁹Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹³Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁴VAMC, Georgetown University, Washington, DC, ¹⁵Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Mortality from cardiovascular (CV) and respiratory causes is increased in rheumatoid arthritis (RA). Predictive serologic biomarkers of these events are lacking. Previously, we have…
Abstract Number: 2127 • 2015 ACR/ARHP Annual Meeting
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Subclinical Coronary Atherosclerosis Is Higher Among Rheumatoid Arthritis Patients with the Lowest Circulating Low Density Lipoprotein Concentrations Compared with Controls
Jon T. Giles¹, Mary Chester M. Wasko², Cecilia P. Chung³, Amy Kao⁴, Sabahat Bokhari⁵, Afshin Zartoshti⁶, C. Michael Stein⁷ and Joan M. Bathon^8,9, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ³Division of Rheumatology & Immunology, Vanderbilt University School of Medicine, Nashville, TN, ⁴Biogen, Cambridge, MA, ⁵Cardiology, Columbia University Medical Center, NY, NY, ⁶Rheumatology, Columbia University Medical Center, NY, NY, ⁷Div of Clinical Pharmacology, Vanderbilt University, Nashville, TN, ⁸Medicine, Columbia University, College, New York, NY, ⁹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Several recent studies have identified RA patients with very low levels of circulating total and low density lipoprotein cholesterol (LDL-C) to be at particularly…
Abstract Number: 3079 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD)
Christopher P. Denton¹, J. Gerry Coghlan², Hossein-Ardeschir Ghofrani³, Friedrich Grimminger³, Jianguo He⁴, Gabriela Riemekasten⁵, Dario Vizza⁶, Annette Boeckenhoff⁷, Christian Meier⁸, Janethe de Oliveira Pena⁹ and Marc Humbert¹⁰, ¹Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom, ²Royal Free London NHS Foundation Trust, London, England, ³University of Giessen and Marburg Lung Center, Giessen, Germany, ⁴Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Clinic of Rheumatology and Clinical Immunology, Berlin, Germany, ⁶La Sapienza University of Rome, Rome, Italy, ⁷Bayer Pharma AG, Wuppertal, Germany, ⁸Bayer Pharma AG, Berlin, Germany, ⁹Bayer HealthCare Pharma, Whippany, NJ, ¹⁰Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France
Background/Purpose: PAH associated with CTD (PAH-CTD) has a worse prognosis than idiopathic/familial PAH. Here we report a prospective subgroup analysis of patients with PAH-CTD from…
Abstract Number: 374 • 2015 ACR/ARHP Annual Meeting
High Prevalence of Osteoporosis and Fractures Is Associated with Abdominal Adiposity and Decreased Muscular Strength in Primary Necrotizing Vasculitides
Karine Briot¹, Bertrand Dunogué², Alexis Regent³, Pascal Cohen², Alice Berezne², Sami Kolta¹, Xavier Puéchal², Claire Le Jeunne⁴, Luc Mouthon⁵, Christian Roux¹, Loïc Guillevin⁶ and Benjamin Terrier², ¹Rheumatology B Department, Hôpital Cochin, Paris, France, ²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ³Service de médecine interne, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Overall survival of primary necrotizing vasculitides, including ANCA-associated vasculitis (AAV) and polyarteritis nodosa (PAN), has greatly improved over the last 50 years. Because of…
Abstract Number: 1508 • 2015 ACR/ARHP Annual Meeting
Lipid Target Achievement Among Patients with Recent-Onset Rheumatoid Arthritis during the First Six Years of Follow-up: Results from a French Multicenter Cohort of Early Arthritis
Anne Tournadre¹, Bruno Pereira², Jean-Jacques Dubost³, Nathalie Rincheval⁴, Anne-Christine Rat^5,6, Bernard Combe⁷ and Martin Soubrier³, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴Lapeyronie Hospital, Montpellier I University, UMR 5535, EA2415, Montpellier, France, ⁵CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁶CHU de Nancy, Rheumatology, Nancy, France, ⁷Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Cardiovascular mortality is increased in rheumatoid arthritis (RA) and RA is an independent risk factor leading to a rapid increase in risk following diagnosis.…
Abstract Number: 1579 • 2015 ACR/ARHP Annual Meeting
Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Natsumi Ikumi^4,5, Hirotake Inomata⁶, Atsuma Nishiwaki⁶, Noboru Kitamura¹, Kaita Sugiyama⁶, Hidetake Shiraiwa⁶, Masataka Nozaki⁶, Yosuke Nagasawa⁶, Yoshihiro Matsukawa⁵ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ⁴Nihon University School of Medicine, Shinjuku, Japan, ⁵Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a multi-organ inflammatory disorder associated with high cardiovascular morbidity and mortality. Cardiac involvements are typically clinically silent, only manifesting as…
Abstract Number: 2129 • 2015 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI
Bara Erhayiem¹, Adam McDiarmid¹, Peter Swoboda¹, Ananth Kidambi¹, David Ripley¹, Tarique Musa¹, Laura Dobson¹, Pankaj Garg¹, Sarah Horton², Raluca Dumitru³, Jacqueline Andrews⁴, John Greenwood⁵, Paul Emery^4,6, Sven Plein¹ and Maya H. Buch^2,7, ¹Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷NIHR - Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Treatment-na•ve, early rheumatoid arthritis patients demonstrate abnormalities of vascular and myocardial function on cardiac MRIB Erhayiem, A McDiarmid, PP Swoboda, A Kidambi, DP Ripley, TA…
Abstract Number: 3084 • 2015 ACR/ARHP Annual Meeting
Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model
Nicholas Young¹, Jeffrey Hampton¹, Saba Aqel¹, Jessica Pyles², Anna Bratasz², Anuradha Kalyanasundaram³, Wael N. Jarjour⁴ and Stacy P. Ardoin⁵, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Small Animal Imaging Core, The Ohio State University Medical Center, Columbus, OH, ³Physiology and Cell Biology, The Ohio State University Medical Center, Columbus, OH, ⁴Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease causing inflammation throughout the body and cardiovascular involvement is a significant contributor to morbidity and mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].